Evidence map›Paper›PMID 40530691›Full record

ArticleNucleic acids research2025

Specific origin selection and excess functional MCM2-7 loading in ORC-deficient cells.

Yoshiyuki Shibata, Mihaela Peycheva, Etsuko Shibata, Daniel Malzl, Rushad Pavri, Anindya Dutta

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Yoshiyuki ShibataDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, United States.
Mihaela PeychevaResearch Institute of Molecular Pathology (IMP), Campus-Vienna-Biocenter- 1, Vienna Biocenter, Vienna 1030, Austria.
Etsuko ShibataDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, United States.
Daniel MalzlResearch Institute of Molecular Pathology (IMP), Campus-Vienna-Biocenter- 1, Vienna Biocenter, Vienna 1030, Austria.
Rushad PavriResearch Institute of Molecular Pathology (IMP), Campus-Vienna-Biocenter- 1, Vienna Biocenter, Vienna 1030, Austria.
Anindya DuttaDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, United States.ORCID 0000-0002-3559-2574

Funding

The role of MCM8-9 in genomic instability of cancersR01CA060499 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Anindya Dutta · 1994 to 2026
$8.6M
Austrian Science FundBoehringer IngelheimIMPNCI NIH HHS R01 CA060499NIH HHS P29163-B26NIH HHS R01 CA060499
6 · The paper itself

Abstract

The six-subunit origin recognition complex (ORC) loads excess MCM2-7 on chromosomes to promote initiation of DNA replication and is believed to be important for origin specification. Mapping of origins in cancer cell lines engineered to delete three of the subunits, ORC1, ORC2, or ORC5, shows that specific origins are still used and are mostly at the same sites in the genome as in wild-type cells. The few thousand origins that were upregulated in the absence of ORC suggest that GC/TA skewness and simple repeat sequences facilitate, but are not essential for, origin selection in the absence of the six-subunit ORC. Despite the lack of ORC, excess MCM2-7 is still loaded at comparable rates in G1 phase to license dormant origins and is also repeatedly loaded in the same S phase to permit re-replication. Thus, origin specification and excess MCM2-7 loading on origins do not require the six-subunit ORC in human cancer cell lines.

Indexed as

DNA ReplicationMinichromosome Maintenance ProteinsOrigin Recognition ComplexReplication OriginCell Line, TumorHumansMinichromosome Maintenance ProteinsORC1 protein, humanOrigin Recognition Complex

Identifiers

PMID40530691
PMCPMC12203792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.